Honasa Consumer buys 58% of Fluence Pharma for ₹135 cr
The Mamaearth parent gains patented cyclical nutrition therapy brands but the deal is tiny relative to its ₹13,690 cr market cap.
— 5 earlier stories on Honasa Consumer Ltd. →What's new
- Honasa acquires 58% of Fluence Pharma for ₹135 cr enterprise value.
- Entry into nutraceuticals with patented cyclical nutrition therapy kits.
- Will incorporate wholly-owned subsidiary Honasa Health for D2C nutraceuticals.
Why this matters
The acquisition opens a new category, doctor-prescribed supplements, but at just 1% of Honasa's market cap the immediate financial impact is negligible. The real test is whether Honasa can scale Fluence's patented therapy into a consumer brand.
What we're watching
- Integration of Fluence's doctor-led distribution network.
- Launch of Honasa Health's D2C nutraceutical brand.
- Remaining 42% stake buyout over 5-7 years.
The full read
Honasa Consumer bought 58% of Fluence Pharma at an enterprise value of ₹135 crore, marking its first move beyond baby and beauty into nutraceuticals. The acquisition opens a new category but at just 1% of Honasa's ₹13,690 crore market cap, the immediate financial impact is negligible. Fluence sells patented, doctor-prescribed supplement kits and generates ₹40 crore in revenue with margins above 20%. Honasa will also set up Honasa Health as a D2C subsidiary. A small bet. More option than statement.
Questions answered
- Why is Honasa acquiring Fluence Pharma?
- To enter the fast-growing nutraceuticals category with patented cyclical nutrition therapy for hair and skin conditions, leveraging Fluence's doctor-prescribed supplement brands.
- How big is the deal relative to Honasa?
- The enterprise value of ₹135 cr is about 1% of Honasa's ₹13,690 cr market cap and 6% of its FY26 standalone revenue of ₹2,305 cr.
- What does Fluence Pharma bring?
- Fluence reported FY26 provisional revenue of about ₹40 cr with an EBITDA margin above 20%. It sells patented supplement kits under brands Hair Fact, Skin Fact, and Pro Fact through a doctor-led network.
- What is Honasa Health?
- A wholly-owned subsidiary Honasa plans to incorporate to build a direct-to-consumer nutraceuticals brand anchored on Fluence's patented cyclical nutrition therapy.
Honasa Consumer Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on HONASA →- 23 Jun 2026 · 6:20 PM IST Honasa Consumer buys 58% of Fluence Pharma for ₹135 cr
- 46d ago Honasa triples EBITDA, pays first dividend, sets five-year targets.
- 46d ago Honasa's FY26 profit jumps 177% to ₹191 cr; maiden dividend of ₹3
- 46d ago Honasa confirms strong FY26 with 177% profit surge, maiden dividend
- 46d ago Honasa posts record Q4 revenue, doubles profit, declares maiden dividend